Retatrutide microdose for appetite and metabolic health
Greenfield describes noticing a marked drop in his appetite for his usual post‑workout smoothie after starting this regimen. He attributes the effect to the systemic, ‘pleotropic’ actions of retatrutide on cardiovascular health, cognition, Alzheimer’s risk, satiety, and lipid management. He contrasts his microdose with the standard 1‑2 mg/week prescribed for weight loss, arguing that the tiny dose avoids the nausea, diarrhea, and mood suppression reported at higher levels while still altering hunger signaling. The peptide is sourced from Pepsul, which mandates a teleconsult with a physician and uses only US‑ or German‑made, screened peptides. Greenfield reconstitutes a 10 mg vial with 5 mL of bacteriostatic water and draws 12.5 units for each injection—a markedly lower volume than therapeutic protocols—and reports sustained results with no desire to increase the dose.
Retatrutide simultaneously activates GLP‑1, GIP, and glucagon receptors. GLP‑1 agonism slows gastric emptying, promotes satiety, and improves insulin secretion; GIP enhances insulin response and lipid metabolism; glucagon receptor activation increases energy expenditure and fat oxidation. The triple‑agonist action yields broad metabolic improvements with less food preoccupation.
Since starting, he has stopped caring about food nearly as much: he went to a post‑pickleball party without eating dinner because the food didn’t appeal to him, waited until 8 pm to make salmon at home, and finds that his smoothie has lost its appeal. He emphasizes that the microdose doesn’t produce the nausea, diarrhea, or depressive symptoms that larger doses can.
I have been injecting a teeny tiny micro dose of something called retatrutide on Monday, Wednesday and Friday mornings. That's a triple hormone receptor agonist. It's a peptide. It targets GLP1. It targets something called GIP and it targets glucagon.

